Food and Drug Administration
Oncologic Drugs Advisory Committee
June 7, 1999
Slides
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Considerations on the Unse of TTP as the Primary Efficacy Endpoint in RCTs of Cytotoxic Drugs for Initial Rx of MBC, Dr. John Johnson, MD htm ppt
Should TTP be a Primary Efficacy Endpoint for First Line Chemotherapy Trials in Metastatic Breast Cancer, Dr. Sandra Swain, MD pdf
Epirubicin (Epirubicin Hydrochloride), Pharmacia & Upjohn htm ppt
NDA 21-010 (NDA 50-778) Epirubicin Hydrochloride Pharmacia & Upjohn, Dr. Susan Honig, MD htm ppt